hit counter
Aurinia Pharmaceuticals Inc. (AUPH) Stock News Sentiment & Price - Sentifly
AUPH - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aurinia Pharmaceuticals Inc. (AUPH)

Canada
Biotechnology
NASDAQ
AUPH Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AUPH Latest news
Business Wire
Neutral
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
2021-11-10 16:05

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees on demand (link here) beginning on Thursday, November 18 at 8 am GMT/3 am EST through Friday, November 19 at 5 pm GMT/12 pm EST. Interested parties can also register and access the

Seeking Alpha
Neutral
Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q3 2021 Results - Earnings Call Transcript
2021-11-03 13:26

Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q3 2021 Results - Earnings Call Transcript

The Motley Fool
Negative
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
2021-11-03 10:15

The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on.

Zacks Investment Research
Negative
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates
2021-11-03 08:26

Aurinia (AUPH) delivered earnings and revenue surprises of -25.81% and -0.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Benzinga
Neutral
Aurinia Pharmaceuticals: Q3 Earnings Insights
2021-11-03 08:05

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Business Wire
Neutral
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
2021-11-03 06:00

VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES

Business Wire
Neutral
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
2021-11-01 10:12

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), a chronic and complex autoimmune

Business Wire
Neutral
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
2021-10-27 07:07

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia's management team will also host a conference call at 8:30 a.m. ET to discuss the Company's financial results and provide general operational and business updates. The conference call and webcast is scheduled for November 3, 2021 8:30 a.m. ET. To part

Business Wire
Neutral
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
2021-10-26 16:10

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE) resulting in potentially life-threatening damage to the kidneys, will be presented at Amer

Zacks Investment Research
Positive
Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?
2021-10-26 06:00

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Loading more news...